Bioxodes is a clinical stage biotech company specialized in the development of novel therapeutics using molecules derived from nature to prevent thrombosis and inflammatory processes.



Bioxodes recently published a review article highlighting the interest of dual inhibition of factor XIIa and XIa as a therapeutic approach for safe thromboprotection.